{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: China Biotechnology news", "home_page_url": "https://sharemaestro.com/newsreel/cn/healthcare/biotechnology/", "feed_url": "https://sharemaestro.com/newsreel/cn/healthcare/biotechnology/feed.json", "description": "Latest Biotechnology company headlines from China, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:89a5af75e31fa462db0c18bd4c32c569218193061a3b233db06acafe4cf16faf", "url": "https://finance.yahoo.com/healthcare/articles/junshi-biosciences-announces-acceptance-supplemental-231000630.html", "external_url": "https://finance.yahoo.com/healthcare/articles/junshi-biosciences-announces-acceptance-supplemental-231000630.html", "title": "Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage \u2161-\u2162 NSCLC", "content_text": "Junshi Biosciences SHANGHAI, July 21, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental application for toripalimab in combination with platinum-containing chemotherapy as perioperative treatment and subsequent monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage II-III non-small cell lung cancer (NSCLC) has been accepted by the Nati", "date_published": "2026-07-21T23:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "688180"], "_sharemaestro": {"country": "China", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "688180", "name": "Shanghai Junshi Biosciences Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/c5520ee0-6aa5-4c47-9f7e-8d388a3694c6/"}]}}]}